All In Biotech

Drug Trial Radar · NCT07104162

A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants With Renal Impairment

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Sep 16, 2025

Primary completion

Sep 4, 2026

Study completion Sep 4, 2026

Sponsor

Lead sponsor
Qpex Biopharma, Inc.Industry
Sponsor type
Industry
Collaborators
Shionogi Inc.; Biomedical Advanced Research and Development Authority
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment

Conditions

  • Bacterial Infections

Interventions

  • Cefiderocol/XeruborbactamDrug

    A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) by participant and by groupTime frame: 11-22 days (+/- 2)
  2. Number of participants with changes from baseline in safety parametersTime frame: 11-22 days (+/- 2)
  3. Maximum plasma concentration measurements by subject and by group (Cmax)Time frame: 11-22 days (+/- 2)
  4. Time to maximum plasma concentration (Tmax)Time frame: 11-22 days (+/- 2)
  5. Area under the plasma concentration versus time curve (AUC)Time frame: 11-22 days (+/- 2)
  6. Cumulative amount of drug excreted as unchanged in the urine (Aeu)Time frame: 11-22 days (+/- 2)
  7. Cumulative amount of drug excreted as unchanged in the dialysate (Aed)Time frame: 11-22 days (+/- 2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami Clinical Pharmacology

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.